Navigation Links
Express Scripts, Inc. Announces Pricing of $4.1 Billion Senior Notes Offering
Date:11/14/2011

acturers, or the significant reduction in payments made or discounts provided by pharmaceutical manufacturers;
  • Changes in industry pricing benchmarks;
  • Results in pending and future litigation or other proceedings which would subject us to significant monetary damages or penalties and/or require us to change our business practices, or the costs incurred in connection with such proceedings;
  • Our failure to execute on, or other issues arising under, certain key client contracts;
  • The impact of our debt service obligations on the availability of funds for other business purposes, and the terms and our required compliance with covenants relating to our indebtedness;
  • Our failure to attract and retain talented employees, or to manage succession and retention for our Chief Executive Officer or other key executives;

  • TRANSACTION-RELATED FACTORS

    • Uncertainty as to whether Express Scripts will be able to consummate the Merger on the terms set forth in the merger agreement;
    • Uncertainty as to our ability to close the offering of the notes;
    • The ability to obtain governmental approvals of the Merger;
    • Uncertainty as to the market value of Express Scripts merger consideration to be paid and the stock component of the Merger consideration;
    • Failure to realize the anticipated benefits of the Merger, including as a result of a delay in completing the Merger or a delay or difficulty in integrating the businesses of Express Scripts and Medco;
    • Uncertainty as to the long-term value of Aristotle (which will be renamed Express Scripts Holding Company) common shares;
    • Limitations on the ability of Express Scripts and Aristotle to incur new debt in connection with the transaction;
    • The expected amount and timing of cost savings and operating synergies; and
    • Failure to receive the approval of the stockholders of either Express
      '/>"/>

    SOURCE Express Scripts, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. ALS TDI Completes Gene Expression Profile of Lou Gehrigs Disease in Mice
    2. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
    3. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
    4. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
    5. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
    6. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
    7. Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients
    8. International Medical Corps Matched with Top 25 American Express Members Project, Saving the Lives of Malnourished Children
    9. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program
    10. SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery
    11. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
    (Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
    (Date:1/14/2014)... InformEx, North America,s leading business ... hold the 30 th edition of its annual conference ... from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... chemical and specialty chemical companies will take part in the ...
    Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
    ... 15 , - Nine-Month Sales (Excluding Technical ... EBITDA Margin at High Level of 17.2% , ... In the first nine months of the financial ... (prior year EUR 783.4m).,Excluding the Technical Plastics business which has been sold, ...
    ... Minn., Oct. 14 AbbeyMoor Medical Inc. ... CPT code by the American Medical Association (AMA) for ... action, effective in January 2010, upgrades The Spanner from ... Category I procedure code for established procedures. This major ...
    Cached Medicine Technology:Gerresheimer has Passed the Turning Point 2Gerresheimer has Passed the Turning Point 3Gerresheimer has Passed the Turning Point 4AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure 2AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure 3
    (Date:7/10/2014)... Reducing the amount of alcoholic beverages consumed, ... including a reduced risk of coronary heart disease, ... according to a new multi-center study published in ... Perelman School of Medicine at the University of ... studies which suggest that consuming light-to-moderate amounts of ...
    (Date:7/10/2014)... students looking to bump up their grade point averages ... time in a library or study hall, but in ... that students who were members of the recreational sports ... and sophomore years had higher GPAs than those who ... with memberships stayed in school longer. An increase of ...
    (Date:7/10/2014)... studies have shown that more severe illness and even ... secondary respiratory infection after developing influenza. Now, however, a ... determined that if you reverse the order of infection, ... may actually protect against a bad case of the ... protein pneumolysin, which is described as a bacterial virulence ...
    (Date:7/10/2014)... cancer were more likely to be diagnosed with ... and survived for shorter times than prostate cancer ... has found. , The negative outcomes may be ... against the mentally ill, depression,s impact on biological ... in his general health and disinterest in receiving ...
    (Date:7/10/2014)... who experience hot flashes are unlikely to talk much ... silent suffering if they are willing to try ... University case study., After seven weeks of hypnotic relaxation ... following prostate cancer surgery showed a drastic decrease not ... in sleep quality, according to the study., The Baylor ...
    Breaking Medicine News(10 mins):Health News:New study shows drinking alcohol provides no heart health benefit 2Health News:Want a higher GPA in college? Join a gym 2Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4
    ... June 18 Roxane Laboratories, Inc.,announced today ... Application (ANDA),for Ramipril Capsules, 1.25mg, 2.5mg, 5mg ... Administration. The 1.25mg, 2.5mg, 5mg and 10mg ... Roxane Laboratories Ramipril,Capsules are available for immediate ...
    ... cancer who had abundant vitamin D in their blood were ... who were deficient in the vitamin, according to a new ... of the study -- the first to examine the effect ... research, but it is too early to recommend supplements as ...
    ... a human patient,s cloned infection-fighting T cells as the sole ... A team led by Cassian Yee, M.D., an associate member ... Center, reports these findings in the June 19 issue of ... and colleagues removed CD4+ T cells, a type of white ...
    ... Authority continues monitoring and evaluating wrong-site surgeries,with ... wrong-site surgery,update, HARRISBURG, Pa., June 18 ... "National Time Out Day," which is a,national ... time out" before every,operation to confirm correct ...
    ... DENVER, June 18 Air Methods Corporation,(Nasdaq: ... in the,world, announced today that Chief Executive Officer ... present at the Jefferies 2nd Annual,Healthcare Conference in ... at 11:15,a.m. ET., Interested parties can listen ...
    ... in Indiana to propose awareness-raising ... legislation in 2009., ... of July as Indiana Safe Haven Month and the,National Safe Haven ... for babies who were adopted thanks to legislation,passed overwhelmingly in the ...
    Cached Medicine News:Health News:Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules 2Health News:Study links vitamin D to colon cancer survival 2Health News:Patient's own infection-fighting T cells put late-stage melanoma into long-term remission 2Health News:Patient Safety Authority Supports 'National Time Out Day' 2Health News:Governor and Lt. Governor Celebrate Eight Years of Safe Haven Babies 2
    Clearview RSV is a simple, immunochromatographic assay to aid in the diagnosis of respiratory syncytial virus (RSV) infections in children less than 6 years and adults over age 60....
    Clearview ULTRA FOB is a rapid, two-step immunochemical test for the detection of fecal occult blood....
    ... RTVue is an ultra-high speed, high resolution ... for retina imaging and analysis. ... Fourier-Domain Optical Coherence technology just emerging from ... The ultra-high speed and high ...
    The Clearview hCG Test is for the rapid detection of human chorionic gonadotropin (hCG) in urine specimens. This test kit is used to obtain a visual, qualitative result and is intended for professio...
    Medicine Products: